ATE476529T1 - Verfahren zur vorhersage und überwachung einer unmittelbaren reaktion auf eine krebstherapie - Google Patents

Verfahren zur vorhersage und überwachung einer unmittelbaren reaktion auf eine krebstherapie

Info

Publication number
ATE476529T1
ATE476529T1 AT06754554T AT06754554T ATE476529T1 AT E476529 T1 ATE476529 T1 AT E476529T1 AT 06754554 T AT06754554 T AT 06754554T AT 06754554 T AT06754554 T AT 06754554T AT E476529 T1 ATE476529 T1 AT E476529T1
Authority
AT
Austria
Prior art keywords
predicting
cancer therapy
immediate response
monitoring
differentially expressed
Prior art date
Application number
AT06754554T
Other languages
English (en)
Inventor
Marc Munnes
Minckwitz Gunther Von
Achim Rody
Thomas Karn
Original Assignee
Siemens Healthcare Diagnostics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Siemens Healthcare Diagnostics filed Critical Siemens Healthcare Diagnostics
Application granted granted Critical
Publication of ATE476529T1 publication Critical patent/ATE476529T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT06754554T 2005-07-08 2006-06-24 Verfahren zur vorhersage und überwachung einer unmittelbaren reaktion auf eine krebstherapie ATE476529T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05014891 2005-07-08
PCT/EP2006/006114 WO2007006408A2 (en) 2005-07-08 2006-06-24 Methods and kits for predicting and monitoring direct response to cancer therapy

Publications (1)

Publication Number Publication Date
ATE476529T1 true ATE476529T1 (de) 2010-08-15

Family

ID=37637515

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06754554T ATE476529T1 (de) 2005-07-08 2006-06-24 Verfahren zur vorhersage und überwachung einer unmittelbaren reaktion auf eine krebstherapie

Country Status (5)

Country Link
US (1) US20090203533A1 (de)
EP (1) EP1904645B1 (de)
AT (1) ATE476529T1 (de)
DE (1) DE602006015966D1 (de)
WO (1) WO2007006408A2 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2036988A1 (de) * 2007-09-12 2009-03-18 Siemens Healthcare Diagnostics GmbH Verfahren zur Vorhersage des Ansprechens eines Tumors auf einen chemotherapeutischen Wirkstoff bei einer Patientin, die unter einer rekurrenten gynäkologischen Krebserkrankung leidet oder Gefahr läuft, eine solche zu entwickeln
WO2011109440A1 (en) 2010-03-01 2011-09-09 Caris Life Sciences Luxembourg Holdings Biomarkers for theranostics
US9771618B2 (en) * 2009-08-19 2017-09-26 Bioarray Genetics, Inc. Methods for treating breast cancer
US20120197539A1 (en) * 2009-10-09 2012-08-02 Carolyn Slupsky Methods for diagnosis, treatment and monitoring of patient health using metabolomics
GB0922085D0 (en) * 2009-12-17 2010-02-03 Cambridge Entpr Ltd Cancer diagnosis and treatment
US9469876B2 (en) 2010-04-06 2016-10-18 Caris Life Sciences Switzerland Holdings Gmbh Circulating biomarkers for metastatic prostate cancer
WO2011153545A2 (en) * 2010-06-04 2011-12-08 Bioarray Therapeutics, Inc. Gene expression signature as a predictor of chemotherapeutic response in breast cancer
EP2742154A4 (de) * 2011-08-08 2015-08-12 Caris Life Sciences Switzerland Holdings Gmbh Biomarkerzusammensetzungen und verfahren damit
WO2014023808A2 (en) * 2012-08-08 2014-02-13 Institut National De La Sante Et De La Recherche Medicale (Inserm) Method for evaluating a cancer patient for propensity to respond to a therapy
WO2014052921A2 (en) * 2012-09-27 2014-04-03 University Of Utah Research Foundation Patient health record similarity measure
WO2017106332A1 (en) 2015-12-14 2017-06-22 X4 Pharmaceuticals, Inc. Methods for treating cancer
CN109069426B (zh) 2015-12-14 2021-10-29 X4 制药有限公司 治疗癌症的方法
EP3393468B1 (de) 2015-12-22 2022-09-14 X4 Pharmaceuticals, Inc. Verfahren zur behandlung einer immunschwächekrankheit
US11337969B2 (en) 2016-04-08 2022-05-24 X4 Pharmaceuticals, Inc. Methods for treating cancer
CN109641838A (zh) 2016-06-21 2019-04-16 X4 制药有限公司 Cxcr4抑制剂及其用途
EP3471726A4 (de) 2016-06-21 2019-10-09 X4 Pharmaceuticals, Inc. Cxcr4-inhibitoren und verwendungen davon
CA3027498A1 (en) 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof
CN107119112B (zh) * 2017-03-30 2020-06-30 中山大学肿瘤防治中心 一种检测肿瘤代谢通路基因表达的引物组、pcr芯片及其应用
CA3080821A1 (en) * 2017-11-07 2019-05-16 X4 Pharmaceuticals, Inc. Cancer biomarkers and methods of use thereof
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040101855A1 (en) * 2002-11-22 2004-05-27 Isis Pharmaceuticals Inc. Modulation of PPAR binding protein expression
EP1365034A3 (de) * 2002-05-21 2004-02-18 Bayer HealthCare AG Verfahren und Zusammensetzungen zur Vorhersage, Diagnose, Prognose, Prävention und Behandlung von malignen Tumoren
JP2005000056A (ja) * 2003-06-11 2005-01-06 Sumitomo Pharmaceut Co Ltd ホルモン依存性癌疾患マーカー及びその利用
WO2005021788A1 (en) * 2003-08-28 2005-03-10 Ipsogen Identification of an erbb2 gene expression signature in breast cancer

Also Published As

Publication number Publication date
DE602006015966D1 (de) 2010-09-16
EP1904645A2 (de) 2008-04-02
WO2007006408A2 (en) 2007-01-18
US20090203533A1 (en) 2009-08-13
EP1904645B1 (de) 2010-08-04
WO2007006408A3 (en) 2007-08-23

Similar Documents

Publication Publication Date Title
ATE476529T1 (de) Verfahren zur vorhersage und überwachung einer unmittelbaren reaktion auf eine krebstherapie
EP1522594A3 (de) Verfahren und kit zur untersuchung von krebs
WO2005119260A3 (en) Methods for predicting and monitoring response to cancer therapy
MX2009012722A (es) Variantes geneticas sobre chr 5p12 y 10q26 como marcadores para el uso en la evaluacion del riesgo, diagnostico, pronostico y tratamiento del cancer de mama.
WO2007015947A3 (en) Methods and kits for the prediction of therapeutic success, recurrence free and overall survival in cancer therapies
HK1148783A1 (zh) 用於乳房腺的預後的基因表達標記
WO2004070062A3 (en) Compositions and methods for diagnosing and treating cancers
WO2007016548A3 (en) Micro-rna-based methods and compositions for the diagnosis, prognosis and treatment of breast cancer
EP3299387A3 (de) Identifizierung von tumorassoziierten markern für diagnose und therapie
WO2005123993A3 (en) Phage microarray profiling of the humoral response to disease
ATE401575T1 (de) Zusammensetzungen und verfahren zur diagnose und behandlung von kolonkrebs
EP1365034A3 (de) Verfahren und Zusammensetzungen zur Vorhersage, Diagnose, Prognose, Prävention und Behandlung von malignen Tumoren
WO2007109236A3 (en) Microrna fingerprints during human megakaryocytopoiesis
WO2004106495A3 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
EA200802242A1 (ru) Способ определения того, будет или не будет пациент респондером на иммунотерапию
EP2285989A4 (de) Neue zielmoleküle zur regulierung von angionese
MX2009010439A (es) Variantes geneticas de chr2 y chr16 como marcadores para el uso en valoracion, diagnosis, prognosis y tratamiento de riesgo de cancer de mama.
WO2003065006A3 (en) Methods and compositions for treating cancer
WO2007033167A3 (en) Compositions and methods for detecting and treating cancer
WO2006037485A3 (en) Methods and kits for the prediction of therapeutic success and recurrence free survival in cancer therapy
WO2001071357A3 (en) Diagnosis and treatment of breast cancer
ATE553112T1 (de) Ttk in der diagnose und als therapeutisches target bei krebs
ATE366936T1 (de) Zusammensetzungen und verfahren zur verwendung von fibronektin-fragmenten bei krebsdiagnose
WO2009013075A3 (en) Markers for invasion in breast and lung carcinoma
EP1635694A4 (de) Verfahren zur diagnose, prognose und behandlung von brustkrebs

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties